

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following was demonstrated in the Phase III StaMINA trial evaluating transplant with RVD consolidation and lenalidomide maintenance versus tandem transplant and lenalidomide maintenance versus single transplant with lenalidomide maintenance?
  - Comparable PFS and OS for the 3 arms
  - Survival advantage with the addition of consolidation and maintenance treatment
  - Survival advantage for tandem transplant
  - None of the above
- Which of the following has been observed regarding the gastrointestinal (GI) side effects associated with ixazomib?
  - GI side effects tend to occur later in the course of therapy as a cumulative effect of treatment
  - GI side effects tend to occur early during the first 3 weeks of treatment
  - GI side effects are rarely observed
- Which of the following has been observed with venetoclax in patients with RRM?
  - A low objective response rate
  - A high objective response rate
  - An objective response rate of 40% to 50% in patients with translocation 11;14
- The addition of bortezomib to up-front treatment with melphalan/dexamethasone in patients with AL amyloidosis results in improved hematologic and organ responses, and bortezomib-containing regimens are a new standard therapy in this setting.
  - True
  - False
- Which of the following was observed in the Phase III GALLIUM study evaluating obinutuzumab- versus rituximab-based induction and maintenance therapy in patients with previously untreated FL?
  - No difference in PFS
  - PFS favored rituximab
  - PFS favored obinutuzumab
- In elderly patients with DLBCL responding to R-CHOP, the addition of lenalidomide maintenance compared to observation resulted in \_\_\_\_\_.
  - A deleterious effect on PFS
  - An improvement in PFS
  - No effect on PFS
- Which of the following was observed in a Phase III trial evaluating the addition of idelalisib to bendamustine/rituximab for patients with relapsed/refractory CLL?
  - Improvement in OS with idelalisib
  - Increased number of opportunistic infections with idelalisib
  - The study was closed early due to idelalisib-associated severe toxicity
  - Both a and b
  - Both b and c
- Vadastuximab talirine is an \_\_\_\_\_.
  - Anti-CD30 monoclonal antibody under investigation in HL
  - Anti-CD33 antibody-drug conjugate under investigation in AML and MDS
  - Anti-CD22 antibody-drug conjugate under investigation in acute lymphoblastic leukemia and CML
- Approximately what percent of patients with MDS or AML who were refractory to prior hypomethylating agents (azacitidine or decitabine) responded to CC-486 (oral azacitidine)?
  - Less than 10%
  - 20%
  - 40%
- Mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 occur in approximately 25% to 30% of patients with AML and represent actionable targets for treatment.
  - True
  - False